Hidroferol Semanal

Hidroferol Semanal is an oral vitamin D analog containing calcifediol monohydrate as its active ingredient. Marketed in the European Union as an OTC product, it is supplied in a weekly dosage form designed to support calcium balance. Calcifediol is the 25‑hydroxy metabolite of vitamin D₃, providing a more rapid increase in circulating vitamin D levels compared with native cholecalciferol. The preparation is intended for individuals with low dietary calcium or vitamin D intake.

Hidroferol Semanal is indicated for the prevention and treatment of vitamin D deficiency and for supporting calcium balance when dietary intake is inadequate.

- Prevention of vitamin D deficiency in adults, adolescents, and elderly individuals. - Treatment of documented low serum 25‑hydroxyvitamin D concentrations. - Adjunctive support for bone health in persons with reduced calcium absorption. - Management of secondary hyperparathyroidism related to vitamin D insufficiency. - Use in individuals with limited sun exposure or malabsorption conditions. - Seasonal supplementation during winter months when endogenous synthesis declines.

Like other vitamin D preparations, Hidroferol Semanal may be associated with a range of adverse reactions, most of which are dose‑related and reversible.

Common: - Mild gastrointestinal discomfort such as nausea or abdominal bloating. - Transient headache or fatigue. - Slight increase in serum calcium without symptoms.

Serious: - Hypercalcemia presenting with polyuria, polydipsia, or cardiac arrhythmia. - Nephrolithiasis (kidney stone formation). - Hypercalciuria leading to renal impairment. - Severe allergic reaction (e.g., urticaria, angioedema).

When using Hidroferol Semanal, certain conditions and patient factors require careful consideration to minimize risk.

- Assess baseline serum 25‑hydroxyvitamin D and calcium levels before initiating therapy. - Use lower weekly doses in patients with renal impairment or a history of hypercalcemia. - Monitor calcium, phosphate, and renal function periodically during long‑term use. - Avoid use in individuals with known hypersensitivity to calcifediol or excipients. - Caution in pregnant or breastfeeding women; consult a healthcare professional. - Consider dose adjustment in elderly patients with reduced renal clearance.

Hidroferol Semanal can affect the pharmacokinetics or pharmacodynamics of several medicines; awareness of these interactions helps maintain safety.

Avoid: - Concomitant high‑dose vitamin D or calcium supplements that may precipitate hypercalcemia. - Thiazide diuretics, which reduce urinary calcium excretion and increase hypercalcemia risk. - Lithium therapy, which can potentiate hyperparathyroidism effects.

Use with caution: - Corticosteroids, which may diminish vitamin D effectiveness and require monitoring. - Anticonvulsants (e.g., phenytoin, phenobarbital) that increase vitamin D metabolism. - Bisphosphonates, where combined effects on calcium balance should be observed. - Loop diuretics, requiring periodic calcium assessment.